204 related articles for article (PubMed ID: 21299739)
1. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.
Björkman S
Haemophilia; 2011 Mar; 17(2):179-84. PubMed ID: 21299739
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy.
Björkman S
Haemophilia; 2013 Nov; 19(6):808-13. PubMed ID: 23786333
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.
Alamelu J; Bevan D; Sorensen B; Rangarajan S
J Thromb Haemost; 2014 Dec; 12(12):2044-8. PubMed ID: 25315324
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring.
Björkman S
Haemophilia; 2013 Sep; 19(5):753-7. PubMed ID: 23731351
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B.
Recht M; Pollmann H; Tagliaferri A; Musso R; Janco R; Neuman WR
Haemophilia; 2011 May; 17(3):494-9. PubMed ID: 21518148
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis.
Björkman S; Shapiro AD; Berntorp E
Haemophilia; 2001 Mar; 7(2):133-9. PubMed ID: 11260271
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
[TBL] [Abstract][Full Text] [Related]
8. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study.
Poon MC; Lillicrap D; Hensman C; Card R; Scully MF
Thromb Haemost; 2002 Mar; 87(3):431-5. PubMed ID: 11916075
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
Preijers T; Hazendonk HCAM; Liesner R; Chowdary P; Driessens MHE; Hart D; Keeling D; Laros-van Gorkom BAP; van der Meer FJM; Meijer K; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH; Mathôt RAA;
J Thromb Haemost; 2018 Nov; 16(11):2196-2207. PubMed ID: 30394056
[TBL] [Abstract][Full Text] [Related]
10. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
Wilmot HV; Hogwood J; Gray E
Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
Brinkhous KM; Sigman JL; Read MS; Stewart PF; McCarthy KP; Timony GA; Leppanen SD; Rup BJ; Keith JC; Garzone PD; Schaub RG
Blood; 1996 Oct; 88(7):2603-10. PubMed ID: 8839853
[TBL] [Abstract][Full Text] [Related]
12. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.
Preijers T; Hazendonk HCAM; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA
J Thromb Haemost; 2017 Sep; 15(9):1737-1746. PubMed ID: 28688133
[TBL] [Abstract][Full Text] [Related]
13. Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).
Solano Trujillo MH; Stasyshyn O; Rusen L; Serban M; Lamas JL; Perina FG; Urasinski T; Oh M; Knowlton WB; Valenta-Singer B; Pavlova BG; Abbuehl B
Haemophilia; 2014 Sep; 20(5):674-81. PubMed ID: 24720694
[TBL] [Abstract][Full Text] [Related]
14. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
Roth DA; Kessler CM; Pasi KJ; Rup B; Courter SG; Tubridy KL;
Blood; 2001 Dec; 98(13):3600-6. PubMed ID: 11739163
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
Björkman S
Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of recombinant factor IX.
White G; Shapiro A; Ragni M; Garzone P; Goodfellow J; Tubridy K; Courter S
Semin Hematol; 1998 Apr; 35(2 Suppl 2):33-8. PubMed ID: 9565165
[TBL] [Abstract][Full Text] [Related]
17. Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010.
Uprichard J; Adamidou D; Goddard NJ; Mann HA; Yee TT
Haemophilia; 2012 Jan; 18(1):46-9. PubMed ID: 21545378
[TBL] [Abstract][Full Text] [Related]
18. EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France.
Polack B; Calvez T; Chambost H; Rothschild C; Goudemand J; Claeyssens S; Borel-Derlon A; Bardoulat I; Maurel F; Woronoff-Lemsi MC;
Transfusion; 2015 Jul; 55(7):1787-97. PubMed ID: 25652955
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan.
Chang HH; Yang YL; Hung MH; Tsay W; Shen MC
J Formos Med Assoc; 2007 Apr; 106(4):281-7. PubMed ID: 17475604
[TBL] [Abstract][Full Text] [Related]
20. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
